Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, announced the retirement of its Chairman Michael J. Finney, Ph.D. from the Board of Directors and Science and Technology Committee, effective September 30, 2025.
The Board of Directors will convene to discuss leadership succession, composition, and governance matters while considering stockholder feedback. The company aims to maintain its focus on advancing its scientific initiatives and oral pill vaccine platform development.
Vaxart (OTCQX: VXRT), azienda biotech in fase clinica che sviluppa vaccini ricombinanti per somministrazione orale in forma di pillola, ha annunciato il pensionamento del suo Presidente Michael J. Finney, Ph.D. dal Consiglio di Amministrazione e dal Science and Technology Committee, con decorrenza 30 settembre 2025.
Il Consiglio si riunirà per discutere la successione della leadership, la composizione e le questioni di governance, tenendo conto dei pareri degli azionisti. L'azienda continuerà a concentrarsi sull'avanzamento delle sue iniziative scientifiche e sullo sviluppo della piattaforma di vaccini in pillola.
Vaxart (OTCQX: VXRT), una empresa biotecnológica en fase clínica que desarrolla vacunas recombinantes orales en formato de píldora, anunció la jubilación de su Presidente Michael J. Finney, Ph.D. del Consejo de Administración y del Comité de Ciencia y Tecnología, con efecto a partir del 30 de septiembre de 2025.
El Consejo de Administración se reunirá para tratar la sucesión en el liderazgo, la composición y asuntos de gobernanza, considerando la opinión de los accionistas. La compañía mantendrá su enfoque en avanzar sus iniciativas científicas y el desarrollo de la plataforma de vacunas en píldora.
Vaxart (OTCQX: VXRT), 경구용 재조합 정제 백신을 개발하는 임상 단계의 생명공학 회사가 이사회 및 과학기술위원회 의장 Michael J. Finney, Ph.D.의 퇴임을 2025년 9월 30일부로 발표했습니다.
이사회는 주주 의견을 반영하여 리더십 승계, 이사회 구성 및 거버넌스 문제를 논의하기 위해 소집될 예정입니다. 회사는 과학적 과제와 경구용 정제 백신 플랫폼 개발을 지속적으로 추진하는 데 주력할 것입니다.
Vaxart (OTCQX: VXRT), une entreprise biotechnologique en phase clinique développant des vaccins recombinants oraux sous forme de pilule, a annoncé la retraite de son président Michael J. Finney, Ph.D. du conseil d'administration et du Science and Technology Committee, effective le 30 septembre 2025.
Le conseil d'administration se réunira pour discuter de la succession à la direction, de la composition et des questions de gouvernance, en tenant compte des retours des actionnaires. L'entreprise entend rester concentrée sur l'avancement de ses initiatives scientifiques et le développement de sa plateforme de vaccins en pilule.
Vaxart (OTCQX: VXRT), ein Biotech-Unternehmen in der klinischen Phase, das orale rekombinante Tablettenimpfstoffe entwickelt, gab den Rücktritt seines Vorsitzenden Michael J. Finney, Ph.D. aus dem Vorstand und dem Science and Technology Committee mit Wirkung zum 30. September 2025 bekannt.
Der Vorstand wird zusammenkommen, um Fragen der Führungsnachfolge, Zusammensetzung und Governance zu erörtern und dabei das Feedback der Aktionäre zu berücksichtigen. Das Unternehmen beabsichtigt, seinen Fokus auf die Weiterentwicklung seiner wissenschaftlichen Initiativen und der Plattform für orale Tablettenimpfstoffe beizubehalten.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 2025.
“It has been a profound privilege to serve as Vaxart’s Chairman and be a part of this incredible Company’s journey for so many years,” said Mr. Finney. “I am immensely proud of what we have accomplished together, and I have the utmost confidence in the team's ability to continue their vital work in advancing its oral pill vaccine platform. I look forward to watching Vaxart's future successes.”
Steven Lo, Chief Executive Officer of Vaxart, commented, “On behalf of the Board and the entire Vaxart team, I want to express our deepest gratitude to Mike for his leadership, wisdom, and steadfast dedication. His contributions have been invaluable to Vaxart’s growth and mission. We wish him all the best.”
The Board of Directors will meet this month to discuss Board leadership, Board composition and other governance issues, taking into account stockholder feedback, with the goal of continuing to advance the Company’s scientific progress.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as “anticipate,” “assume,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under “Item 1A - Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this communication.
Contact
Vaxart Media and Investor Relations
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
FAQ
When is Michael J. Finney retiring from Vaxart's Board of Directors?
What positions did Michael J. Finney hold at Vaxart (VXRT)?
What type of vaccines does Vaxart (VXRT) develop?
What are Vaxart's next steps following Chairman Finney's retirement?
